Scarica l'app Stockscreener
21.64
1.57%
-0.3499
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ACAD Giù?
Forum
Previsione
Acadia Pharmaceuticals Inc Borsa (ACAD) Ultime notizie
Why ACADIA Pharmaceuticals Inc. (ACAD) Skyrocketed on Friday - Insider Monkey
ACADIA Pharmaceuticals (ACAD): Analyst Raises Price Target to $2 - GuruFocus
Acadia Pharmaceuticals (ACAD) Sees Price Target Uplift After Pat - GuruFocus
Insider Sell Alert: Mark Schneyer Sells 2,000 Shares of ACADIA P - GuruFocus
ACADIA Pharmaceuticals Executives Sell Shares - TradingView
ACAD: Mizuho Raises Price Target for ACADIA Pharmaceuticals | AC - GuruFocus
ACAD: Mizuho Raises Price Target for ACADIA Pharmaceuticals | ACAD Stock News - GuruFocus
ACADIA Pharmaceuticals (ACAD) Sees Boost in Price Target by Baird | ACAD Stock News - GuruFocus
ACADIA Pharmaceuticals (ACAD): RBC Capital Reiterates Outperform Rating | ACAD Stock News - GuruFocus
Acadia Pharmaceuticals (ACAD) Wins Key Patent Case for Nuplazid | ACAD Stock News - GuruFocus
ACADIA Pharmaceuticals (ACAD) Price Target Raised by BMO Capital - GuruFocus
BMO Capital Boosts Acadia Pharmaceuticals (ACAD) Price Target Fo - GuruFocus
Scott+Scott Attorneys at Law LLP Announce a Notice of Pendency of Class Action in the Acadia Pharmaceuticals, Inc. Securities Litigation - PrimePublishers.com
ACAD Stock Soars as US Court Rules in Favor of Key Nuplazid Patent - TradingView
ACADIA Pharmaceuticals (ACAD) Sees Price Target Raised by Analys - GuruFocus
Forecasting The Future: 8 Analyst Projections For ACADIA Pharmaceuticals - Benzinga
Mizuho Boosts Price Target for Acadia Pharmaceuticals (ACAD) | A - GuruFocus
Netflix To $1,220? Here Are 10 Top Analyst Forecasts For Monday - Benzinga
Baird Lifts Price Target for Acadia Pharmaceuticals (ACAD) Amid Patent Victory | ACAD Stock News - GuruFocus
Acadia Pharmaceuticals (ACAD) Price Target Raised Amid Patent Victory | ACAD Stock News - GuruFocus
ACAD: Needham Raises Price Target to $30, Maintains Buy Rating | - GuruFocus
Stocks To Watch: ACADIA Pharmaceuticals Sees Relative Strength Rating Jump To 93 - Investor's Business Daily
Acadia Pharmaceuticals price target raised to $19 from $17 at Oppenheimer - Yahoo Finance
Acadia Nuplazid patent ruling removes ‘key overhang,’ says BMO Capital - Yahoo Finance
Acadia Pharmaceuticals: Another Legal Win, ACP-101 Readout Preview (NASDAQ:ACAD) - Seeking Alpha
Acadia Pharmaceuticals secures patent protection for Parkinson’s drug By Investing.com - Investing.com South Africa
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q1 2025 Earnings Call Transcript - MSN
Healthcare Stocks Lifted By Legal Wins And Drug Approvals - Finimize
Sector Update: Health Care - marketscreener.com
Acadia Pharmaceuticals secures patent protection for Parkinson’s drug - Investing.com Australia
Acadia Pharmaceuticals (ACAD) Wins Key Patent Case for Nuplazid - GuruFocus
Acadia Pharmaceuticals jumps after win in patent suit over Nuplazid - MSN
Acadia (ACAD) Wins Patent Dispute, Secures Future Revenues | ACAD Stock News - GuruFocus
Delaware District Court Rules in Favor of Acadia in NUPLAZID® (p - GuruFocus
Acadia Wins Nuplazid Patent Case in Delaware Court; Shares Surge - marketscreener.com
Acadia confirms court ruling in favor of Nuplazid formulation patent - TipRanks
Acadia Pharmaceuticals (ACAD) Wins Patent Infringement Case Agai - GuruFocus
Acadia Pharmaceuticals (ACAD) Sees Price Target Increase from Ne - GuruFocus
Oppenheimer Raises Price Target for Acadia Pharmaceuticals (ACAD - GuruFocus
Acadia Pharma (ACAD) announces that Delaware Court has ruled in its favor for NUPLAZID litigation - StreetInsider
Delaware District Court Rules In Favor Of Acadia In Nuplazid Formulation Patent Litigation - marketscreener.com
Oppenheimer Raises Price Target for Acadia Pharmaceuticals (ACAD) | ACAD Stock News - GuruFocus
Delaware District Court Rules in Favor of Acadia in NUPLAZID® (pimavanserin) Formulation Patent Litigation - Yahoo Finance
Acadia Wins Patent Ruling Over Aurobindo’s Nuplazid Copies (2) - Bloomberg Law News
Evolv Technologies, Quantum Computing, ACADIA Pharmaceuticals And Other Big Stocks Moving Higher On Friday - Benzinga
Acadia Pharmaceuticals (ACAD) Soars Following Patent Victory - GuruFocus
Acadia Pharmaceuticals (ACAD) Wins Patent Infringement Case | ACAD Stock News - GuruFocus
Acadia Pharmaceuticals shares surge on patent ruling By Investing.com - Investing.com South Africa
Acadia Pharmaceuticals shares surge on patent ruling - Investing.com
Acadia Pharmaceuticals jumps after win in patent suit over Nuplazid (ACAD:NASDAQ) - Seeking Alpha
Acadia Pharmaceuticals at BofA Conference: Strategic Growth Plans - Investing.com Australia
Acadia Pharmaceuticals at BofA Conference: Strategic Growth Plans By Investing.com - Investing.com India
Transcript : ACADIA Pharmaceuticals Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 03 - marketscreener.com
ACADIA Pharmaceuticals: Advancing On Several Fronts (NASDAQ:ACAD) - Seeking Alpha
Acad projects $244.3M Q1 revenue with DAYBUE and NUPLAZID growth, anticipates accelerated Prader-Willi trial data - MSN
Acadia Pharmaceuticals files to sell 43.58M shares of common stock for holders - MSN
Acadia Q1 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth - MSN
Investor Network: ACADIA Pharmaceuticals Inc. to Host Earnings Call - ACCESS Newswire
Acadia Pharmaceuticals (ACAD) Prepares for Stock Sale by Shareho - GuruFocus
Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings and Revenue Estimates (Revised) - Yahoo Finance
Acadia Pharmaceuticals Inc Files For Offering Of Up To 43.6 Million Shares Of Common Stock By The Selling StockholdersSEC Filing - marketscreener.com
Acadia Pharmaceuticals (ACAD) Prepares for Stock Sale by Shareholders - GuruFocus
Acadia Pharma (ACAD) Files for 43.58M Share Offering by Selling Stockholders - StreetInsider
New Parkinson's Disease Therapies Market Outlook & Research - openPR.com
ACADIA Pharmaceuticals Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - simplywall.st
0.78%
1.61%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):